Format

Send to

Choose Destination
Oncotarget. 2017 Feb 21;8(8):13986-14002. doi: 10.18632/oncotarget.14753.

Protein S drives oral squamous cell carcinoma tumorigenicity through regulation of AXL.

Author information

1
Institute for Dental Sciences, Faculty of Dental Medicine, The Hebrew University of Jerusalem, Israel.
2
Department of Oral Medicine, The Hebrew University - Hadassah School of Dental Medicine, Jerusalem, Israel.

Abstract

The TAM family of proto-oncogenic receptor protein tyrosine kinases, comprising of TYRO3, AXL, and MERTK, is implicated in many human cancers. Their activation leads to cancer cell proliferation, enhanced migration, invasion, and drug resistance; however how TAMs are activated in cancers is less understood. We previously showed that Protein S (PROS1) is a ligand of the TAM receptors. Here we identify PROS1 as a mediator of Oral Squamous Cell Carcinoma (OSCC) in proliferation, cell survival and migration. We demonstrate that excess PROS1 induces OSCC proliferation and migration. Conversely, blocking endogenous PROS1 expression using shRNA significantly inhibits cell proliferation and migration in culture. This inhibition was rescued by the addition of purified PROS1. Moreover, PROS1 knockdown reduced anchorage-independent growth in-vitro, reduced tumor xenograft growth in nude mice and altered their differentiation profile. Mechanistically, we identify the downregulation of AXL transcripts and protein following PROS1 knockdown. Re-introducing PROS1 rescues AXL expression both at the protein and transcriptional levels. The anti-proliferative effect of the AXL inhibitor R428 was significantly reduced following PROS1 inhibition, indicating the functional significance of PROS1-mediated regulation of AXL in OSCC. Taken together, we identify PROS1 as a driver of OSCC tumor growth and a modulator of AXL expression. Our results point to PROS1 as a potential novel anti-cancer therapeutic target.

KEYWORDS:

AXL; OSCC; PROS1; protein S; squamous cell carcinoma

PMID:
28118606
PMCID:
PMC5355156
DOI:
10.18632/oncotarget.14753
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center